First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

The FDA has approved the first generic version of Priftin (rifapentine; Sanofi-Aventis US) tablets for both active and latent tuberculosis (TB) treatment protocols.¹ Rifapentine is a key component of several Center for Disease Control and Prevention (CDC)-recommended regimens for latent TB infection. An estimated 13 million people in the United States are living with latent TB infection, underscoring the importance of maintaining access to effective preventive therapies.²

The entry of a generic equivalent offers a timely intervention for health care systems and payers. State health departments have actively monitored TB following a multiyear postpandemic surge in domestic TB cases.³ 

Clinical Indications and Target Populations

The FDA's approval delineates 2 separate clinical indications across adult and pediatric populations. The generic tablets are indicated for the treatment of active pulmonary TB caused by Mycobacterium TB in patients aged 12 years and older. It must be administered in combination with 1 or more other antituberculosis drugs to which the patient’s clinical bacterial isolate is fully susceptible.

The drug is also approved to treat latent tuberculosis infection (LTBI) caused by Mycobacterium TB in patients aged 2 years and older who are deemed at high risk of progressing to active disease. In this preventative scenario, rifapentine must be used in combination with isoniazid.

Safety Profiles, Contraindications, and Clinical Guardrails

The prescribing information for the generic rifapentine tablets retains the same safety profiles, contraindications, and precautions as the brand-name reference drug. The treatment is strictly contraindicated in any patient with a known history of hypersensitivity to rifapentine or any other rifamycin-class antibiotics (such as rifampin or rifabutin).

Clinical warnings highlight risks for potential hepatotoxicity, requiring baseline and periodic liver function monitoring. Additional precautions include severe cutaneous adverse reactions, hypersensitivity or systemic drug-related reactions, and extensive cytochrome. Clinical teams should also advise patients that rifapentine tablets may produce a benign, red-orange discoloration of body tissues and fluids such as urine, sweat, tears, and saliva.

Adverse reaction profiles vary depending on the patient's specific indication and prescribed regimen. For individuals undergoing treatment for active pulmonary TB, the most common adverse effects meeting or exceeding a 3% threshold include anemia, lymphopenia, neutropenia, thrombocytosis, hemoptysis, cough, increased sweating, elevated liver enzymes, back pain, rash, anorexia, arthralgia, increased blood urea, and headache. Conversely, for individuals utilizing the less intensive preventative LTBI regimen, the single most common adverse reaction occurring in 3% or more of patients is a hypersensitivity reaction.

Formulary Impact and Supply Considerations

For managed care executives and public health formulary directors, generic rifapentine provides an opportunity for direct cost containment. By potentially offering an affordable generic alternative to brand-name Priftin, payers and state health departments can better scale targeted "test-and-treat" protocols without unsustainable budgetary impacts, enhancing compliance across historically underserved or vulnerable populations.

Providers and clinical pharmacists are encouraged to consult the FDA’s official Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book, to review therapeutic equivalence ratings. Health systems and payers should coordinate directly with generic manufacturers regarding immediate product availability and rollout timelines to ensure seamless integration into preventive health formularies.

References

1. US Food and Drug Administration. FDA approves first generic of Priftin (rifapentine) tablets. Published June 23, 2026. Accessed June 23, 2026. URL. https://content.govdelivery.com/accounts/USFDA/bulletins/41d514b 
2. Centers for Disease Control and Prevention. Latent TB infection in the United States: published estimates. Updated March 26, 2026. Accessed June 23, 2026. https://www.cdc.gov/tb-data/latent-tb-infection-estimates/index.html
3. Williams AS, Wortham PM, Crane RJ, et al. Tuberculosis — United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(12):265–270. doi:10.15585/mmwr.mm7312a4